Elimination half-life and bioavailability of haloperidol in schizophrenic patients.
Haloperidol was administered orally to 6 male schizophrenic patients and intravenously to 3. Elimination half-life (t1/2 beta) and bioavailability (F) were calculated for both groups from haloperidol serum concentrations determined by gas-liquid chromatography. Mean (+/- SD) half-lives were 17.5 +/- 8.7 hours for oral administration and 15.1 +/- 2.5 hours for intravenous; bioavailability was 0.64 +/- 0.23. These values were comparable to those found in normal volunteers.
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D002908:Chronic Disease; D006207:Half-Life; D006220:Haloperidol / Q000008:administration & dosage / Q000378:metabolism*; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy* / Q000378:metabolism
D006220:Haloperidol